ArticleThe Journal of clinical investigation2022

BCG therapy downregulates HLA-I on malignant cells to subvert antitumor immune responses in bladder cancer.

Mathieu Rouanne et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.